effect
durat
diseas
frequenc
bowel
motion
agent
could
meet
need
would
therefor
use
addit
ort
diosmectit
natur
aluminomagnesium
silic
clay
lamellar
nonfibr
crystallin
structur
give
strong
adsorb
properti
mechan
action
yet
fulli
understood
probabl
multipl
diosmectit
reduc
inflamm
modifi
mucu
rheolog
properti
inhibit
mucolysi
adsorb
bacteria
bacteri
enterotoxin
virus
potenti
diarrheogen
substanc
number
studi
shown
diosmectit
reduc
durat
diarrhea
decreas
frequenc
bowel
motion
day
treatment
children
mildtomoder
acut
diarrhea
two
recent
trial
indic
reduct
stool
output
diosmectit
favor
safeti
profil
seriou
advers
effect
diosmectit
frequent
use
mainli
european
countri
also
asia
africa
diosmectit
use
adjunct
altern
ort
need
antibacteri
therapi
acut
diarrhea
defin
diarrheal
diseas
consist
passag
unform
wateri
stool
three
time
per
day
last
day
persist
chronic
diarrhea
diarrheal
diseas
last
day
respect
diarrhea
occur
result
nonspecif
intestin
respons
variou
stimuli
includ
infect
drug
inflammatori
bowel
diseas
acut
diarrhea
attribut
variou
infecti
caus
although
infect
organ
often
identifi
invas
diarrhea
occur
infect
pathogen
cross
mucos
line
gastrointestin
gi
tract
virus
particularli
rotaviru
predomin
pathogen
associ
diarrhea
develop
countri
bacteria
frequent
caus
develop
region
diarrhea
occur
absorpt
secretori
chang
increas
volum
water
enter
colon
level
beyond
absorpt
capac
almost
alway
aris
result
one
four
basic
mechan
osmot
diarrhea
secretori
diarrhea
exud
diarrhea
diarrhea
associ
motil
disord
osmot
diarrhea
occur
larg
quantiti
poorli
absorb
low
molecularweight
solut
lumen
drive
transport
excess
water
lumen
via
osmot
forc
secretori
diarrhea
develop
respons
overstimul
secretori
capac
intestin
tract
usual
occur
result
bacteri
viral
enterotoxin
exud
diarrhea
bacteri
viral
pathogen
destroy
epitheli
cell
disrupt
tight
junction
intestin
epithelium
allow
water
electrolyt
mucu
protein
exud
lumen
due
hydrostat
pressur
differenti
may
accumul
caus
diarrhea
motil
disord
acceler
intestin
transit
time
decreas
absorpt
caus
diarrhea
even
absorpt
process
proceed
normal
diarrhea
major
contributor
global
morbid
mortal
despit
recent
advanc
understand
pathogenesi
diagnosi
treatment
enter
diseas
less
well
recogn
consequ
caus
infecti
diarrhea
also
includ
condit
irrit
bowel
syndrom
hemolyticurem
syndrom
malnutrit
factor
environ
also
play
import
role
pathogenesi
infecti
diarrheal
diseas
mass
food
process
global
food
suppli
increas
intern
travel
emerg
spread
resist
bacteria
factor
contribut
diarrheal
diseas
concern
develop
develop
countri
although
sharp
declin
diarrheaassoci
mortal
develop
countri
still
preval
diseas
associ
signific
econom
burden
develop
countri
particularli
vulner
consequ
diarrhea
acut
gastroenter
character
acuteonset
diarrhea
without
vomit
nausea
fever
abdomin
pain
symptom
sign
may
nonspecif
children
estim
billion
case
acut
gastroenter
caus
gi
tract
infect
annual
among
children
age
year
previous
approxim
million
children
age
year
die
year
consequ
acut
gastroenter
predominantli
develop
countri
figur
decreas
consider
last
decad
mainli
result
improv
manag
condit
gastroenter
typic
selflimit
condit
main
goal
therapi
prevent
complic
secondari
dehydr
associ
electrolyt
disturb
metabol
acidosi
oral
rehydr
salt
or
solut
recommend
mainstay
treatment
acut
diarrhea
effect
case
mild
moder
dehydr
oral
rehydr
therapi
ort
or
solut
obviou
advantag
intraven
iv
fluid
rehydr
less
costli
abl
administ
mani
set
includ
home
case
sever
dehydr
ort
contraind
patient
unabl
drink
iv
rehydr
may
requir
initi
earli
reintroduct
ort
possibl
continu
feed
includ
breast
feed
also
import
children
acut
diarrhea
consid
feasibl
soon
first
part
rehydr
finish
ie
hour
ort
central
manag
acut
diarrhea
reduc
frequenc
bowel
movement
durat
ill
altern
adjunct
antidiarrh
agent
decreas
durat
diarrhea
safe
would
therefor
valuabl
addit
manag
diarrhea
three
main
class
antidiarrh
drug
use
reduc
stool
frequenc
volum
durat
symptom
antimotil
agent
antisecretori
adsorb
howev
import
drug
use
treat
diarrhea
particularli
children
safe
well
toler
especi
like
use
home
environ
without
extens
physician
supervis
antidiarrh
agent
also
abl
use
conjunct
ort
effect
diarrhea
differ
etiolog
antidiarrh
agent
usual
recommend
acut
diarrhea
children
mainli
lack
consist
efficaci
data
support
use
pediatr
patient
also
potenti
signific
seriou
advers
effect
associ
antimotil
antisecretori
agent
adsorb
hand
gener
well
toler
readili
absorb
system
diosmectit
smectit
smecta
ipsen
boulognebillancourt
franc
oral
formul
natur
aluminomagnesium
silic
clay
lamellar
structur
exhibit
adsorb
properti
interact
mucu
shown
effect
well
toler
antidiarrh
agent
reduc
frequenc
stool
durat
symptom
see
section
review
summar
pharmacodynam
activ
diosmectit
underli
antidiarrh
properti
evalu
clinic
evid
use
diosmectit
treatment
diarrhea
children
articl
use
review
identifi
within
medlin
databas
use
search
term
diosmectit
smectit
addit
refer
identifi
bibliographi
publish
articl
histor
practic
geophagi
report
contin
go
back
hundr
year
particularli
tropic
region
also
seen
anim
kingdom
use
salt
lick
mud
wallow
clay
use
system
prevent
poison
treat
diarrhea
indigest
topic
treatment
skin
mouth
ulcer
parasit
erad
soil
histor
use
purpos
typic
found
rich
kaolin
miner
particularli
smectit
clay
continu
use
today
varieti
indic
addit
use
antidiarrh
agent
focu
articl
resurg
use
clay
complementari
therapist
mani
indic
describ
section
use
clay
includ
beauti
treatment
lubric
drill
sealant
emulsifi
bleach
agent
inde
clay
extract
bentonit
use
backfil
materi
underground
storag
facil
radioact
nuclear
materi
diosmectit
powder
formul
oral
suspens
natur
clay
form
fine
sheet
aluminomagnesium
silic
nonfibr
crystallin
structur
diosmectit
confer
significantli
greater
adsorb
properti
clay
use
treatment
diarrhea
diosmectit
reduc
inflamm
inhibit
penetr
toxin
mucu
layer
thu
interven
intestin
lumen
epitheli
cell
see
section
efficaci
diosmectit
treatment
acut
diarrhea
children
investig
sever
control
clinic
studi
despit
vari
inclus
criteria
outcom
paramet
result
consist
demonstr
efficaci
diosmectit
largest
trial
date
children
age
month
year
acuteonset
mildtomoder
diarrhea
random
receiv
or
plu
diosmectit
g
day
or
therapi
alon
day
efficaci
assess
accord
total
durat
diarrhea
stool
frequenc
consist
incid
vomit
fever
number
children
diarrhea
last
day
number
children
requir
hospit
adjunct
therapi
diosmectit
significantli
improv
frequenc
stool
output
stool
consist
day
compar
or
alon
day
treatment
differ
improv
treatment
group
signific
diarrhea
last
day
affect
fewer
children
receiv
diosmectit
plu
or
or
alon
vs
p
outcom
hospit
admiss
incid
durat
vomit
fever
differ
treatment
group
diosmectit
well
toler
treatmentrel
advers
event
report
children
compli
diosmectit
regimen
includ
refus
even
one
dose
commonli
report
reason
noncompli
unpleas
tast
diosmectit
formul
compar
control
toler
data
report
placebocontrol
studi
boy
age
month
acut
wateri
diarrhea
mild
moder
sever
dehydr
random
receiv
follow
rehydr
therapi
diosmectit
g
four
time
daili
day
placebo
unlik
previou
studi
patient
complet
regimen
treatment
administ
supervis
mean
durat
diarrhea
diosmectit
recipi
significantli
shorter
placebo
recipi
vs
hour
p
differ
group
becam
statist
signific
hour
start
treatment
diosmectit
also
associ
significantli
fewer
diarrheal
stool
overal
vs
p
weight
gain
hour
significantli
greater
diosmectit
despit
compar
fluid
food
intak
group
diosmectit
well
toler
interfer
normal
feed
ort
two
similarli
design
studi
thailand
evalu
efficaci
accept
safeti
diosmectit
hospit
outpati
pediatr
patient
age
month
mildtomoder
acut
diarrhea
studi
hospit
patient
infant
random
receiv
diosmectit
g
everi
hour
depend
bodyweight
combin
or
n
or
alon
n
durat
diarrhea
almost
halv
diosmectit
recipi
vs
hour
p
day
infant
receiv
diosmectit
continu
diarrhea
compar
treat
or
alon
outpati
studi
infant
random
receiv
rehydr
plu
diosmectit
g
everi
hour
n
iv
oral
rehydr
alon
n
diarrhea
resolv
diosmectit
recipi
day
treatment
compar
infant
receiv
rehydr
alon
p
day
treatment
incid
diarrhea
diosmectit
group
compar
rehydrationalon
group
p
accept
diosmectit
rate
good
children
outpati
studi
tendenc
patient
diosmectit
group
experi
constip
studi
three
case
outpati
studi
two
particip
studi
hospit
infant
harden
stool
two
hospit
infant
refus
medic
vomit
difficulti
resolv
move
diosmectit
administr
preprandi
period
diosmectit
combin
or
also
shown
effect
or
alon
random
openlabel
multicent
studi
involv
children
age
month
hospit
lithuania
acut
diarrhea
mild
moder
dehydr
diosmectit
significantli
reduc
durat
diarrhea
compar
or
alon
vs
hour
p
electrolyt
level
also
evalu
sodium
level
increas
significantli
treatment
group
level
exceed
normal
level
normal
patient
hyponatrem
dehydr
suggest
diosmectit
impact
absorpt
electrolyt
treatmentrel
advers
effect
occur
studi
gilbert
et
al
compar
efficaci
diosmectit
loperamid
placebocontrol
studi
involv
children
age
month
moder
sever
diarrhea
mostli
secondari
rotaviru
infect
resolut
diarrhea
occur
day
diosmectit
loperamid
respect
compar
day
placebo
differ
diosmectit
loperamid
signific
although
toler
data
formal
obtain
studi
treat
physician
report
toler
good
case
current
studi
directli
compar
efficaci
diosmectit
antimotil
drug
antisecretori
drug
adsorb
agent
recent
metaanalysi
random
control
clinic
trial
includ
mani
clinic
studi
cite
previous
review
tabl
six
trial
n
found
diosmectit
significantli
reduc
durat
diarrhea
mean
hour
ci
compar
control
data
two
trial
n
show
frequenc
stool
reduc
hour
hour
start
treatment
diosmectit
compar
placebo
differ
diosmectit
placebo
evid
hour
rel
chanc
resolut
diarrhea
day
diosmectit
treatment
ci
compar
control
statist
signific
number
patient
need
treat
resolv
one
case
diarrhea
ci
analys
detect
differ
diosmectit
placebo
incid
vomit
complianc
treatment
avail
toler
data
indic
nonsignific
trend
diosmectit
placebo
recipi
experi
constip
acknowledg
limit
inher
metaanalysi
methodolog
limit
includ
studi
investig
conclud
result
metaanalysi
promis
suggest
children
acut
diarrhea
may
benefit
use
diosmectit
howev
also
caution
diosmectit
use
patient
parent
physician
need
mind
focu
remov
appropri
rehydr
electrolyt
nutrit
therapi
investig
also
note
well
conduct
research
need
determin
patient
eg
age
invad
pathogen
type
outpati
vs
inpati
gain
greatest
clinic
benefit
effect
dose
regimen
cost
effect
otherwis
therapi
toler
diosmectit
recent
two
random
parallel
doubleblind
placebocontrol
studi
peru
n
malaysia
n
undertaken
examin
efficaci
diosmectit
reduc
stool
output
children
age
month
acut
diarrhea
inclus
criteria
includ
wateri
stool
day
hour
weight
height
ratio
addit
ort
formula
patient
receiv
diosmectit
g
day
children
age
month
g
day
children
age
month
day
follow
half
dose
complet
recoveri
stool
output
significantli
lower
diosmectit
particularli
among
rotavirusposit
children
pool
data
mean
stool
output
g
kg
observ
diosmectit
group
versu
g
kg
placebo
group
p
pathophysiolog
diarrhea
intestin
epitheli
cell
trigger
larg
immun
respons
pathogen
organ
adhes
invas
enter
pathogen
stimul
inflammatori
respons
adjac
intestin
mucosa
via
number
differ
mechan
figur
bacteri
invas
result
coordin
express
upregul
proinflammatori
cytokin
epitheli
cell
also
demonstr
intestin
epitheli
cell
infect
microb
exampl
enteropathogen
escherichia
coli
epec
inflammatori
respons
mediat
nuclear
factorkb
activ
inde
mani
enter
pathogen
capabl
activ
inflammatori
respons
secret
chlorid
main
determin
hydrat
lumen
main
chlorid
transport
affect
pathogen
cystic
fibrosi
transmembran
conduct
regul
cftr
calciumdriven
chlorid
channel
cholera
enterotoxin
e
coli
type
ii
heat
labil
enterotoxin
clostridium
difficil
exampl
activ
cftr
via
induct
cyclic
adenosin
monophosph
camp
stimul
electrogen
chlorid
secret
ultim
lead
diarrhea
chlorid
secret
also
stimul
via
cyclic
guanosin
monophosph
cgmp
mediat
pathway
heatstabl
enterotoxin
produc
enteroaggreg
e
coli
enterotoxigen
e
coli
etec
nonbacteri
pathogen
especi
rotaviru
also
associ
product
viral
glycoprotein
enterotoxin
associ
intracellular
calciumdriven
chlorid
secret
tabl
signific
clinic
effect
diosmectit
compar
control
random
control
trial
effect
diosmectit
studi
includ
patient
result
ci
mean
reduct
durat
diarrhea
guarino
et
al
lachaux
et
al
madkour
et
al
narkeviciut
et
al
vivatvakin
et
al
zong
et
al
h
weight
mean
differ
frequenc
diarrhea
madkour
et
al
h
osman
et
al
h
weight
mean
differ
total
number
stool
madkour
et
al
rel
chanc
cure
lachaux
et
al
lexomboon
et
al
madkour
et
al
vivatvakin
et
al
nnt
number
need
treat
stop
diarrhea
last
day
one
patient
rr
risk
ratio
diosmectit
children
acut
diarrhea
pathogen
trigger
inflammatori
respons
level
intestin
mucosa
caus
disrupt
intestin
barrier
result
heighten
cross
macromolecul
includ
antigen
therebi
probabl
facilit
selfperpetu
process
mucos
inflamm
inflamm
destroy
mucosa
caus
diarrhea
colon
epitheli
cell
may
program
provid
chemotact
activ
signal
nearbi
immun
inflammatori
cell
follow
pathogen
invas
furthermor
tumor
necrosi
factor
tnf
interleukin
il
produc
neighbor
cell
within
epitheli
microenviron
follow
microbi
invas
stimul
product
proinflammatori
cytokin
epitheli
cell
amplifi
mucos
inflammatori
respons
bacteri
invas
shown
result
coordin
express
upregul
proinflammatori
cytokin
epitheli
cell
mani
pathogen
produc
endotoxin
also
contribut
pathophysiolog
acut
diarrhea
disrupt
calcium
camp
cgmpmediat
fluid
electrolyt
secret
alter
tight
junction
barrier
function
activ
inflammatori
pathway
tight
junction
epitheli
cell
disrupt
enter
pathogen
either
alter
cellular
cytoskeleton
affect
specif
tight
junction
protein
c
perfringen
bacteroid
fragili
vibrio
cholera
known
interfer
tight
junction
barrier
mechan
action
diosmectit
three
broad
mechan
diosmectit
thought
help
treatment
diarrhea
ultim
involv
disrupt
interact
intestin
lumen
intestin
epitheli
cell
first
diosmectit
reduc
inflamm
secondli
bind
mucu
barrier
alter
rheolog
properti
inhibit
mucolysi
thirdli
adsorb
toxin
compound
infecti
agent
damag
mucu
line
antiinflammatori
mechan
diosmectit
probabl
involv
inhibit
proinflammatori
marker
diosmectit
demonstr
signific
antiinflammatori
activ
experiment
rat
model
hapteninduc
coliti
furthermor
level
antiinflammatori
action
compar
establish
treatment
sulfasalazin
possibl
antiinflammatori
mechan
includ
adsorpt
lumin
antigen
produc
inflamm
process
increas
colon
mucin
level
modul
cytokin
product
mucos
cell
sever
effect
proinflammatori
cytokin
demonstr
contribut
antiinflammatori
effect
diosmectit
see
section
diosmectit
bind
mucu
layer
intestin
induc
physicochem
chang
mucopolysaccharid
alter
rheolog
properti
droy
et
al
show
pretreat
rat
diosmectit
provid
protect
morpholog
damag
caus
bile
salt
effect
believ
relat
reduc
penetr
toxin
mucu
layer
rateau
et
al
investig
effect
diosmectit
rabbit
ileum
model
mucolysi
control
sucras
proteas
enzym
produc
pathogen
bacteria
diosmectit
inhibit
mucolysi
reduc
destruct
lumin
surfac
membran
epitheli
cell
anim
infect
epec
diosmectit
influenc
mucu
level
uninfect
anim
anesthet
rat
diosmectit
protect
adher
gastric
mucu
layer
pepsininduc
mucolysi
administ
minut
prior
pepsin
challeng
given
hour
prior
pepsin
challeng
diosmectit
abl
prevent
gastric
mucos
hemorrhag
histolog
epitheli
damag
mucin
degrad
also
significantli
reduc
rat
receiv
diosmectit
minut
hour
pepsin
challeng
reduct
signific
diosmectit
administ
hour
pepsin
challeng
diosmectit
also
found
effect
increas
thick
mucu
layer
rat
shortli
administr
thick
greatest
measur
declin
maximum
hour
administr
histolog
find
suggest
diosmectit
mix
adher
mucu
rather
form
two
separ
layer
addit
bind
mucu
layer
diosmectit
may
also
inhibit
action
pepsin
evid
inhibit
pepsininduc
mucolysi
rat
receiv
diosmectit
believ
diosmectit
exert
action
mucu
least
part
bind
mucin
therebi
protect
damag
result
presenc
inflamm
diosmectit
significantli
increas
colon
express
mucin
main
secretori
gelform
mucin
colon
howev
effect
posttranscript
gene
messeng
rna
level
unchang
diosmectit
vivo
data
vivo
anim
studi
vitro
experi
indic
diosmectit
abl
protect
intestin
mucosa
adsorb
bacteria
bacteri
toxin
virus
intestin
irrit
increas
gastric
empti
associ
administr
trichothecen
mycotoxin
reduc
mice
pretreat
diosmectit
day
earlier
diosmectit
incub
toxin
hour
prior
administr
howev
diosmectit
effect
gastric
empti
administ
concurr
toxin
prior
incub
diosmectit
administ
also
effect
gastric
empti
indic
effect
depend
presenc
toxin
fact
incub
toxin
diosmectit
vitro
prior
administr
effect
prevent
acceler
gastric
empti
suggest
diosmectit
may
abl
adsorb
toxin
howev
find
diosmectit
normal
elimin
within
hour
protect
confer
diosmectit
administ
day
toxin
support
addit
mechan
independ
adsorpt
toxin
smectit
stomach
abil
diosmectit
adsorb
e
coli
v
cholera
heatlabil
toxin
etec
heatstabl
toxin
enterohemorrhag
e
coli
verotoxin
investig
cell
cultur
newborn
mice
ph
intestin
chyme
diosmectit
effici
adsorb
labil
toxin
hydrogen
bond
prevent
fixat
toxin
cellular
membran
receptor
diosmectit
adsorb
verotoxin
acid
environ
alkalin
ph
stabl
toxin
slightli
adsorb
diosmectit
shown
complet
bind
c
difficil
toxin
b
c
c
perfringen
enterotoxin
vitro
dilut
partial
bind
observ
greater
dilut
c
difficil
endotoxin
bound
diosmectit
dilut
studi
also
demonstr
diosmectit
effect
bacteri
growth
effect
metronidazol
vitro
abil
diosmectit
minim
effect
c
difficil
enterotoxin
b
also
observ
mccoy
cell
line
studi
also
show
diosmectit
abl
elimin
toxic
effect
enterotoxin
b
fragili
incub
human
colon
adenocarcinoma
cell
line
clark
et
al
investig
adsorpt
rotaviru
coronaviru
vitro
varieti
adsorpt
agent
diosmectit
one
agent
includ
investig
howev
given
test
agent
show
excel
virusadsorb
properti
tempt
specul
diosmectit
may
also
possess
capabl
compar
control
diosmectit
significantli
reduc
level
inhibit
increas
synthesi
myeloperoxidas
normal
seen
colit
rat
suggest
decreas
neutrophil
infiltr
activ
monocyt
would
consist
decreas
antigen
load
scenario
support
decreas
level
induc
nitric
oxid
synthas
histolog
find
diosmectit
may
also
modul
mucos
inflammatori
respons
use
human
epitheli
cell
line
model
interfac
diosmectit
colon
epithelium
investig
found
diosmectit
dose
depend
inhibit
basolater
secret
intestin
epitheli
cell
respons
lipopolysaccharid
stimul
one
import
proinflammatori
cytokin
releas
epitheli
cell
follow
penetr
endotox
endotoxinbear
pathogen
diosmectit
also
dose
depend
reduc
level
produc
human
monocyt
cell
line
cell
respons
lipopolysaccharid
stimul
suggest
diosmectit
may
potenti
greater
antiinflammatori
activ
integr
epithelium
impair
howev
must
note
find
vitro
studi
evid
abil
diosmectit
act
lumin
side
intestin
epithelium
reduc
consequ
inflamm
aris
studi
investig
effect
apic
diosmectit
intestin
dysfunct
induc
basal
tnfa
incub
monolay
intestin
cell
line
tnfa
interferong
alter
intestin
barrier
function
result
paracellular
leakag
epitheli
layer
addit
diosmectit
complet
restor
barrier
capac
epitheli
layer
measur
signific
reduct
ionic
conduct
mannitol
horseradish
peroxidas
flux
furthermor
diosmectit
found
effect
permeabl
absenc
tnfa
diosmectit
found
decreas
gastric
jejun
colon
motil
dog
day
treatment
absenc
diarrheaproduc
stimuli
cholera
toxin
also
administ
diosmectit
administ
day
later
appear
restor
cholera
toxininduc
disrupt
gi
cyclic
activ
mannitol
infus
disrupt
gastric
jejun
cyclic
migrat
motor
complex
stimul
colon
motil
activ
result
diarrhea
minut
start
infus
mannitol
infus
administ
day
diosmectit
initi
disrupt
gastric
jejun
activ
persist
disturb
colon
motil
absent
develop
diarrhea
delay
hour
investig
postul
diosmectit
probabl
enhanc
fluid
absorpt
mechan
differ
effect
suggest
diosmectit
may
differ
mechan
differ
section
gi
tract
variou
condit
addit
preclin
evid
effect
diosmectit
intestin
permeabl
investig
children
acut
gastroenter
patient
receiv
diosmectit
g
three
four
time
daili
depend
bodyweight
placebo
diosmectit
significantli
improv
urinari
mannitol
clearanc
day
treatment
compar
placebo
find
intestin
absorpt
mannitol
superior
diosmectit
recipi
suggest
absorpt
capabl
intestin
increas
diosmectit
diosmectit
alter
net
ion
flux
fluid
chang
favor
absorpt
consequ
counteract
microbialinduc
water
excret
rabbit
ileal
mucosa
expos
etec
effect
believ
secondari
reduc
bacteri
mucolysi
diminish
destruct
lumin
surfac
membran
intestin
epithelium
microbi
pathogen
chlorid
magnesium
adsorpt
increas
bicarbon
secret
decreas
diosmectit
goblet
cell
degrad
amelior
increas
absorpt
magnesium
indic
cellular
integr
preserv
find
could
contribut
antidiarrh
effect
diosmectit
infecti
diarrhea
human
diosmectit
avail
countri
frequent
use
good
effect
reduc
durat
diarrhea
howev
current
recommend
routin
use
children
acut
diarrhea
addit
cost
efficaci
ort
recent
recommend
use
zinc
adjunct
therapi
ort
treatment
acut
diarrhea
children
date
studi
shown
whether
concomit
use
diosmectit
affect
zinc
absorpt
howev
note
adsorb
properti
diosmectit
administ
differ
time
medic
although
costeffect
studi
publish
possibl
addit
cost
diosmectit
offset
reduc
durat
diseas
length
hospit
stay
time
spent
parent
look
children
diarrhea
also
propos
diosmectit
might
use
manag
infecti
diarrhea
extens
use
antibacteri
agent
led
emerg
multiresist
organ
strain
precis
process
es
diosmectit
act
decreas
diarrhea
yet
establish
appear
quit
complex
impair
structur
function
intestin
mucosa
alway
occur
infecti
diarrhea
antidiarrh
properti
diosmectit
probabl
includ
protect
damag
intestin
mucosa
diarrheogen
agent
current
data
suggest
multipl
mechan
may
contribut
antiinflammatori
effect
like
decreas
proinflammatori
cytokin
report
sever
studi
secondari
effect
occur
lumen
diosmectit
absorb
lumen
epitheli
cell
therefor
probabl
inhibit
pathogen
lumen
induc
inflamm
gut
wall
propos
mechan
diosmectit
act
lumin
level
includ
increas
thick
mucu
layer
absorpt
bind
endotoxin
absorpt
protein
antigen
associ
inflamm
increas
colon
mucin
decreas
mucolysi
may
also
secondari
enterotoxin
adsorpt
previous
mention
section
rateau
et
al
determin
diosmectit
inhibit
mucolysi
caus
epec
infect
studi
acknowledg
smectit
may
inhibit
mucolysi
adsorb
enterotoxin
therebi
mask
action
goblet
cell
diarrhea
probabl
decreas
antiinflammatori
effect
diosmectit
result
amelior
increas
fluid
secret
normal
associ
inflamm
chang
absorpt
properti
intestin
presenc
diosmectit
may
also
alter
fluid
electrolyt
secret
absorpt
may
also
contribut
antidiarrh
effect
tempt
deduc
data
diosmectit
act
physic
barrier
proinflammatori
mechan
data
show
diosmectit
provid
antidiarrh
activ
sever
day
administr
time
would
elimin
intestin
lumen
suggest
also
like
reinforc
effect
natur
defens
mechan
contribut
overal
antiinflammatori
effect
signific
effect
diosmectit
stool
output
also
recent
demonstr
primari
outcom
two
placebocontrol
trial
young
children
acut
diarrhea
although
design
aim
studi
show
diosmectit
particularli
effect
rotavirusposit
children
effect
could
relat
higher
stool
output
rotavirusposit
patient
pharmacolog
properti
diosmectit
may
also
relat
fact
pharmacolog
effect
like
demonstr
symptom
pronounc
addit
reason
may
rotaviru
induc
secretori
process
enterocyt
level
could
counteract
diosmectit
oral
antibacteri
may
also
indic
patient
diarrhea
diosmectit
consid
replac
antibacteri
therapi
indic
eg
invas
diarrhea
furthermor
effect
diosmectit
gi
system
oral
administ
drug
may
inadequ
absorb
given
concomitantli
therefor
delay
minut
administr
diosmectit
oral
antibacteri
oral
administ
agent
reli
absorpt
recommend
ort
hand
advers
affect
administ
concomitantli
diosmectit
conclus
diosmectit
demonstr
adsorb
antiinflammatori
activ
vivo
vitro
studi
sever
mechan
diosmectit
treat
diarrhea
diosmectit
reduc
inflamm
probabl
via
direct
modulatori
effect
cytokin
product
mucos
cell
bind
mucu
barrier
alter
rheolog
properti
inhibit
mucolysi
increas
colon
mucin
diosmectit
also
shown
adsorb
toxin
compound
damag
mucu
line
includ
bacteri
enterotoxin
virus
enhanc
absorpt
capabl
gut
vivo
although
ort
remain
cornerston
treatment
mildtomoder
acut
diarrhea
sever
control
clinic
trial
children
mildtomoder
acut
diarrhea
provid
evid
diosmectit
significantli
reduc
stool
output
durat
diarrhea
stool
frequenc
time
improv
stool
consist
incid
protract
case
diarrhea
ie
day
lack
system
absorpt
diosmectit
also
well
toler
even
young
children
administ
adjunct
ort
without
affect
absorpt
efficaci
antibacteri
agent
need
administ
least
minut
diosmectit
efficaci
diosmectit
assess
mainli
eight
control
studi
children
develop
develop
countri
mildtomoder
acut
diarrhea
hospit
ambulatori
set
studi
determin
cost
effect
diosmectit
combin
ort
would
also
use
